linjc16/ctgov huggingface dataset:
Chronic Pain After Amputation

Study Overview
=================
Brief Summary
-----------------
This trial will test the effectiveness of amitriptyline in relieving chronic pain of adults that have had an amputation

Detailed Description
-----------------
This double-masked placebo controlled trial will randomize patients (n=125) who are 6 months or more after amputation and have a 3 or more month history of pain to a daily dose of amitriptyline or a placebo for 6 weeks. Patients will receive a complete functional neurological examination by one of the study physicians or nurses masked to their treatment assignment. Study participants will also be interviewed by telephone to assess pain, pain interference with activities, physical and mental health, and number of health care visits for pain, at the beginning and end of the six-week trial and four months later.

Official Title
-----------------
Management of Chronic Pain in Rehabilitation Project II Management of Chronic Pain in Persons With Amputation

Conditions
-----------------
Amputation, Traumatic, Pain, Postoperative Pain

Intervention / Treatment
-----------------
* Drug: Amitriptyline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Amputation six months ago or longer Pain for 3 months or longer Exclusion Criteria: History of cardiovascular disease, seizures, or glaucoma Currently taking antidepressant medications Currently hyperthyroid or taking thyroid medication Currently pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Amitriptyline|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Amputation, Chronic Pain, Amitriptyline
Diagnosis of Short Stature in Children : Study of a Cohort of Small-sized Consulting Patients

Study Overview
=================
Brief Summary
-----------------
Many patients consult in pediatric endocrinology because of their small size. In the majority of cases, this growth delays can be explained by a hormonal, gastroenterological cause, or a chronic disease. Sometimes the reason for stunted growth can be constitutional bone disease, a genetic cause of short stature that is still underdiagnosed. The investigators wish to describe and take stock of the various additional analyzes carried out and the various diagnoses made in patients who consulted in endocrino-pediatrics at the Montpellier University Hospital due to their short stature, in 2017 and 2018, in order to better screen patients with constitutional bone disease

Official Title
-----------------
Diagnosis of Short Stature in Children : Study of a Cohort of Small-sized Consulting Patients in 2017 and 2018

Conditions
-----------------
Short Stature, Growth Delay

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: All the children who consulted for the first time because of their short stature, in pediatric endocrinology at the Montpellier University Hospital between January 2017 and December 2018 Exclusion criteria: Patient already undergoing specialized medical follow-up due to his small size Major patient

Ages Eligible for Study
-----------------
Maximum Age: 17 Years


Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study the prevalence of different diagnoses of stature delay in children | Study the prevalence of different diagnoses of stature delay in children | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Constitutional bone disease, Pediatrics
Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications

Study Overview
=================
Brief Summary
-----------------
i-gel C-LMA Compare the effect on gastroeosephageal reflux Postoperative complicatios.

Detailed Description
-----------------
120 ASA I-II adult patients. Patients were randomised into two groups i-gel C-LMA Volume controlled ventilation, general anesthesia Asses Gastroeosephageal reflux, sore throat, coughing, dysphagia,dysphonia recorded.

Official Title
-----------------
Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications

Conditions
-----------------
Bladder Tumour, Prostate Hyperplasia

Intervention / Treatment
-----------------
* Device: i-gel
* Device: C-LMA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I-II Adult Elective surgery Bladder tumour Prostat hyperplasi Exclusion Criteria: Emergency surgery Hiatal hernia Gastroeosephageal reflux disease

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: i-gel<br>i-gel placed after induction | Device: i-gel<br>* i-gel placed after induction<br>* Other names: supraglottic airway device;|
| Active Comparator: C-LMA<br>C-LMA placed after induction | Device: C-LMA<br>* placed after induction<br>* Other names: supraglottic airway device;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ph MEASUREMENT | The ph of the secretions on the airway device will be measurd with a Ph-meter | 1 MİNUTE AFTER EXTUBATİON | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bleu dye on the airway device | The airway device will be examined with fiberoptic endoscope after placement | 5 min after placenent | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
i-gel, C-LMA, gastroeosephageal reflux, sore troat
Evaluating Quality of Life in Patients With Soft Tissue Sarcoma Presenting With Metastatic Lung Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the role of palliative surgery in improving Quality of Life (QoL) and symptom control for patients who present with a Soft Tissue Sarcoma (STS) and metastatic lung disease. Responses to clinical Edmonton Symptom Assessment System - Sarcoma Modified ( ESAS-SM) questionnaire for patients who have undergone surgery for resection of the primary tumour will be compared to those that are unable to have surgery. Data collected from this questionnaire can highlight the benefits in patients' QoL who receive palliative surgical resection, and whether these benefits surmount those who are not treated with palliative surgery.

Official Title
-----------------
Evaluating Quality of Life in Patients With Soft Tissue Sarcoma Presenting With Metastatic Lung Disease Using the ESAS-Sarcoma Modified Questionnaire

Conditions
-----------------
Soft Tissue Sarcoma, Metastatic Lung Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with soft tissue sarcoma with at least one pulmonary metastasis Metastatic lung disease must have been present at time of initial presentation Exclusion Criteria: All patients under 18 will be excluded Patients who have been previously undergone surgical resection of the primary tumor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Palliative Surgery Group<br>Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt to proceed with palliative surgical treatment | |
| Non-surgical Group<br>Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt not to pursue palliative surgery | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in QoL score using patient-response questionnaire | The Edmonton Symptom Assessment System - Sarcoma Modified ( ESAS-SM) questionnaire will be completed at baseline, 6 weeks and 3, 6, 12, 24, 36 and 60 months post presentation/surgical intervention. | questionnaire will be obtained at initial presentation and at up to 7 additional visits (6 weeks, 3 months, 6 months, 12 months, 24 months, 36 months and 60 months after initial presentation or treatment) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non-surgical, palliative surgery
Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults

Study Overview
=================
Brief Summary
-----------------
The investigators at Rockefeller University are doing this research to study how the immune system responds to viruses and other infectious agents by using the yellow fever 17D vaccine as a model. The YFV-17D vaccine is one of the safest and most effective vaccines known and has been used to vaccinate humans against yellow fever virus (YFV) infection since the 1930s. By studying how the human immune system responds to the YFV vaccine we hope to learn more about the normal functioning of the immune system so that it might be possible to design new, more effective types of vaccines to prevent important infectious diseases. The reason for doing this research is: Currently there is very little information about which factors determine the effectiveness of the initial (primary) immune response to a foreign substance (antigen), such as a virus, that person may be exposed to. There is also very little known about what determines how effectively and for how long a person's immune system can react to the same antigen to prevent another infection. Studies in animals have given us important information about how the immune systems of other animals behave upon initial or repeated exposure to antigens,but these topics have not been studied in detail in humans. The following hypotheses will be tested: The magnitude of the initial expansion of T lymphocytes (the clonal burst) specific for the infecting virus determines the level at which memory T cell responses are generated against the specific viral antigen and the duration of the memory T cell response generated in the body. The majority of CD8 T cells generated after immunization are yellow fever specific and not bystander activation of non-specific cells.

Official Title
-----------------
Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults

Conditions
-----------------
Yellow Fever

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Able to give informed consent. Age 18-45 years. Agrees not to take any vaccines within 30 days before or 30 days after YFV vaccination. Exclusion Criteria: Previously vaccinated with yellow fever vaccine. A history of a medical condition resulting in impaired immunity. Use of immunosuppressive medications. Thymus gland dysfunction. Recipient of a blood product or immune globulin product within 42 days of the screening visit or 30 days after the YFV vaccination.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Yellow Fever
Twisted Fallopian Tubes

Study Overview
=================
Brief Summary
-----------------
Isolated tubal torsion is a very rare event already in adults (1: 1.5 million women), it remains exceptional in children without being able to find a prevalence in the literature. The causes can be malformative or idiopathic, but even that remains unknown. Because of the scarcity, surgical treatment is not standardized and left to the good care of the surgeon in charge.

Official Title
-----------------
Long Term Follow-up of Twisted Fallopian Tubes Among Young Girl. International Study

Conditions
-----------------
Twisted Fallopian Tube

Intervention / Treatment
-----------------
* Procedure: Surgery of twisted fallopian tubes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient younger then 18 going through surgery for twisted fallopian tubes Exclusion Criteria: Girl above 18 and tubal torsion associated with ovary torsion

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Twisted fallopian tubes cohort<br>Description of girls who went through surgery for twisted fallopian tubes | Procedure: Surgery of twisted fallopian tubes<br>* Patients diagnosed with twisted fallopian tube go through surgery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fallopian tube Surgery results | Evaluation of twisted fallopian surgery interest on then long terms, define as percentage of patients going through surgical revision | Evaluation 10 years after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Twisted Fallopian Tube
Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to tests the hypothesis, that N-acetylcysteine (a thiol-antioxidant)improves the exercise training effect on cancer patients that experience weight loss (cachexia) as assessed by muscle mass and function as well as histomorphology.

Official Title
-----------------
Effect of N-Acetylcysteine on Skeletal Muscle in Cachectic Cancer Patients Undergoing a Resistance Training Program (Phase 2 Study)

Conditions
-----------------
Gastrointestinal Neoplasms, Bronchial Carcinoma, Hodgkin Disease, Non-Hodgkin Lymphoma, Weight Loss

Intervention / Treatment
-----------------
* Drug: N-acetylcysteine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: gastrointestinal or bronchial cancer weight loss of 10% within 6 months sufficient mobility Exclusion Criteria: severe pain, steroid therapy, severe internal, muscular, neurological, psychiatric disease, N-acetylcysteine allergy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: N-acetylcysteine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| muscle cross-sectional area, peak forces |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| muscle fiber composition (biopsy vastus lateralis muscle mRNA levels of cytokines, myostatin. Activity of Akt-dependent pathways |  |  | 
| muscle 31Phospho-magnetic-resonance spectroscopy |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer cachexia, muscle wasting, weight loss, proteolysis
The Effect of Physical Activity on the Brain

Study Overview
=================
Brief Summary
-----------------
Physical activity is thought to increase overall body functions and to decrease cardiovascular and stroke risk factors. Now the question arose, wether enhanced exercise could also exert positive influence on cognition in the aging brain. Therefore, 50 to 80 years old healthy subjects take part in a prospective study with regular sports activity during 6 months. Cognitive functions are detected with sensitive neuropsychological outcome measures, further investigations include MRT of the head, lactat- and other physical measures as well as detailed serum profiles. As a hypothesis, enhanced physical activity is suggested to predict better cognitive performance.

Official Title
-----------------
Clinical Study on the Effect of Physical Activity on Cognition and Memory in the Elderly

Conditions
-----------------
Aerobic Exercise, Anaerobic Exercise, Unchanged Condition

Intervention / Treatment
-----------------
* Behavioral: exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 50-80 years old healthy lesser activity Exclusion Criteria: regular physical activity diabetes stroke heavy smoking, drinking, BMI < 20 MMSE < 25

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Aerobic Exercise<br> | Behavioral: exercise<br> <br> |
| Experimental: Anaerobic Exercise<br> | Behavioral: exercise<br> <br> |
| No Intervention: Unchanged condition<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of reaction times in ms in a motor learning task after 6 months of intervention/control condition |  | 6 months | 
| Change of delayed memory scores in #of words in a Verbal learning task after 6 months of intervention/control condition |  | 6 months | 
| Change of performance in ms in a reaction time task after 6 months of intervention/control condition |  | 6 months | 
| Change of relative regional grey matter volumes in % measured by T1-weighted MRI after 6 months of intervention/control condition |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of physical measurements (ECG)/fitness assessments (lactate) after 6 months of intervention/control condition |  | 6 months | 
| Change of BDNF blood serum levels in ng/dl after 6 months of intervention/control condition |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
exercise, physical activity, cognition, brain, aging, BDNF
Late Sequelae of Bronchopulmonary Dysplasia

Study Overview
=================
Brief Summary
-----------------
To measure the cardiopulmonary function in individuals who developed bronchopulmonary dysplasia (BPD) at Stanford University Medical Center from 1964-1973 and to determine the factors associated with the presence of cardiopulmonary function abnormalities in these adolescents and young adults.

Detailed Description
-----------------
BACKGROUND: Eleven to 22 percent of prematurely born human infants with Respiratory Distress Syndrome (RDS) treated with artificial ventilation and supplemental oxygen therapy, develop a severe chronic lung disease called bronchopulmonary dysplasia. While many children who had BPD are asymptomatic by three years of age, some can have respiratory symptoms and abnormal pulmonary function tests at nine years of age. The hypothesis tested in this study is that abnormalities of pulmonary function seen in infants with BPD can persist into adolescence, even in asymptomatic children and young adults. DESIGN NARRATIVE: A detailed interval pulmonary history was taken. Pulmonary abnormalities were determined by pulmonary angiography and lateral chest x-ray and pulmonary function tests for small airway obstruction, reversible bronchial hyperreactivity, distribution of ventilation, air trapping and hyperinflation, residual interstitial disease or edema, vascular bed loss, and gas exchange. Right and left ventricular hypertrophy were evaluated by electrocardiogram. Elevated right ventricular pressure was estimated by echocardiography with doppler ultrasound. The atopic status of the children was determined. Other abnormalities, including growth retardation, developmental delay, hearing loss, retrolental fibroplasia, and neurologic disability seen in BPD were assessed by history and physical examination.

Conditions
-----------------
Lung Diseases, Bronchopulmonary Dysplasia

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |